Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Immix Biopharma Inc IMMX

Healthcare Biotechnology
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMMX)

Immix Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire 5 days ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

GlobeNewswire January 28, 2026

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire December 9, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

GlobeNewswire December 7, 2025

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

GlobeNewswire November 12, 2025

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

GlobeNewswire November 3, 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire October 14, 2025

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

GlobeNewswire October 6, 2025
View More News ››

Opinion & Analysis (NDAQ:IMMX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMMX)

New video out!!

https://youtu.be/R7prawxnVoU?si=DnsOKNjSkQnwNNcq
BryceCanada - December 3, 2025

Excellent new coverage on IMMX

https://youtu.be/vWcjkHFWLKM?si=aKKoq1grOldvzzxL
BryceCanada - August 27, 2024

New coverage on IMMX!

https://youtu.be/616ReCUzJuA?si=vqEmN8RLDA309UM3
BryceCanada - December 6, 2023

How does great News

Turn into a drop in the SP.............WTF
silverT - May 3, 2023

Wow huge jump today!

https://youtu.be/JFSoXiLB2Ks
BryceCanada - December 14, 2022

IMMX....has done well this a.m....

I'd say its at resistance here at $2.40 Cheers !
Iseneschal - December 14, 2022
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »

Podcasts